Inactive Instrument
Company Vical Incorporated Nasdaq
Stocks
US9256022032
Biotechnology & Medical Research
Business description: Vical Incorporated
Sales by Activity: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Geographical breakdown of sales: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
United States | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Executive Committee: Vical Incorporated
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 74 | - |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 2015-12-31 |
Aaron Fox-Collis
DFI | Director of Finance/CFO | - | 2022-05-31 |
Aron Aizenstat
PRN | Corporate Officer/Principal | - | - |
Sue Fattor
HRO | Human Resources Officer | - | - |
Company details: Vical Incorporated
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.19% | -3.19% | +44.60% | +87.98% | 72.13B | |
| -15.86% | -16.16% | +2.68% | +50.90% | 49.41B | |
| -2.39% | +0.50% | +3.41% | +31.33% | 47.24B | |
| -6.35% | -8.63% | +293.39% | +651.28% | 40.32B | |
| +0.30% | -0.71% | +29.05% | +30.33% | 42.61B | |
| -3.82% | -2.41% | -0.27% | +101.36% | 39.81B | |
| -2.13% | -2.18% | +7.51% | +50.31% | 30.52B | |
| -3.35% | -4.95% | -13.38% | -17.22% | 23.13B | |
| -5.27% | +1.86% | +12.19% | -5.34% | 21.09B | |
| Average | -4.67% | -3.66% | +42.13% | +108.99% | 40.7B | |
| Weighted average by Cap. | -4.85% | -3.85% | +45.72% | +117.28% |
